

Viltolarsen (Viltepso) Patient Referral Form

Admissions Fax # 844-878-6917
Admissions Phone # 855-WF-R-RARF (855-937-7273)

				Aumission	13 F11011E # 855-WE-	IN-INAINE (855-	331-12131		
Patient Demo	graphics Infor	mation				laan	la aa		
Patient Name						SSN#	DOB		
Patient Address									
Primary Phone				Cellular Phone			Work Phone		
Emergency Contact Name, Relationship						Emergency Contact Phone Number			
Additional Do		Needed							
				y and Physical /diff, BMP, & CMP -to-creatinine ratio		 ♠ Recent vitals including blood pressure ♠ Confirmation of DMD gene mutation 			
Patient Insura			,						
Insurance Plan #1				Insurance Plan #2					
Subscriber Name			DOB		Subscriber Name		DOB		
Policy Number (Policy Number	Number		Group ID	
Patient Clinica	al Information	1							
\square M \square F	Height (inches)	Weight (lbs.) Allergies (food/drug)							
	Medical Nece	ssity / Primary		osis					
CD10: Description of diagnosis:									
Medication In	formation / P	rescription and	d Order	rs					
Medication:	Directions:	ections:				Quantity/Refills			
		Infuse intravenously per manufacturer guidelines over 60 minutes.					Dispense: #4 doses (one month)		
Viltepso *If calculated dos			se is less than 100 mL, dilute with sodium chloride 0.9% to a total			+ refills			
		volume of 100 m	L. If calcu	lated dose is 100	mL or more, further dilution	on not required.			
□ DMD dosing:	ma (S	ROmg/kg) intrave	nously (nnce weekly	*If natient is currently tak	ing Viltenso	☐ Other		
□ DMD dosing: mg (80mg/kg) intravenously once weekly. *If patient is currently taking Viltepso, date of last dose:									
□ Other dosing:	mg i	ntravenously eve	ery	week(s)	44.5 5. 145.5 4555.				
Premedication	n(s)						Quantity/Ref	ills	
☐ Give premedication(s) 30 minutes prior to infusion (generics will be dispensed)							Dispense: #QS + 12 refills		
diphenhy	drAMINE	☐ Pediatric Dosing:mg (1mg/kg/dose) PO ☐ Adult Dosing: 25-50mg PO					unless otherwise noted		
Acetamin	ophen	☐ Pediatric Dosing:mg (10-15mg/kg/dose) PO ☐ Adult Dosing: 325-650mg PO							
							ng) 🗆 Other		
☐ Lidocaine 2.5% and Prilocaine 2.5% topical cream: Apply to IV site prior to access PRN for pain upon needle insertion.									
☐ Other (prescribe	r to specify):								
Line Access							Quantity/Ref	ills	
RN to start peripheral IV or use existing CVAD. RN to administer catheter flushing and medications per Heritage Biologics policy.								Dispense: quantity #QS	
☐ Sodium Chloride 0.9% 10 mL Flush: Flush with 2-10 mL sodium chloride 0.9% IV before and after medication administration								PRN refills	
or every 24 hours while IV access in place.								unless otherwise noted	
□ Sodium Chloride 0.9% 10 mL STERILE Flush: Flush with 5-10 mL STERILE sodium chloride 0.9% as needed for port access									
☐ Heparin Lock 10 units/mL 5 mL Flush: Lock with 2-5 mL heparin 10 units/mL after each use or daily while port accessed. ☐ Other ☐ Heparin Lock 100 units/mL 5 mL Flush: Lock with 2-5 mL heparin 100 units/mL after each use or daily while port accessed.									
Adverse React		ISII. LOCK WITH 2-3 IIII	перапп	too units/int after e	acti use of daily wrille port act	cesseu.			
		use influsion for 10	minutos	than rasuma infi	usion at previously tolerate	nd rate and use an	propirato modical	management	
		on and notify phys		, then resume init	ision at previously tolerate	tu rate and use ap	propirate medical	management	
Prescriber Information									
Physician Name					Office Contact				
Practice Address									
NPI#			License # Practice Phon			Practice Phone			
Physician Signaturo	Required - Substitu	ition Permitted	Date Physician Signature Requ			red - Dispense as Written Date		Date	
Physician Signature Required - Substitution Permitted					, Joseph Jignature Required	C Dispense do Wille			